지카바이러스 치료제 시장 : 시장 규모, 점유율, 성장 분석 - 백신 유형별, 검사 유형별, 최종 사용자별, 지역별 산업 예측(2025-2032년)
Zika Virus Therapeutics Market Size, Share, and Growth Analysis, By Vaccine Type (Inactivated Virus Vaccine, Live Attenuated Vaccine), By Test Type (Molecular Test, Serological Test), By End User, By Region - Industry Forecast 2025-2032
상품코드:1758659
리서치사:SkyQuest
발행일:2025년 06월
페이지 정보:영문 198 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 지카바이러스 치료제 시장 규모는 2023년 20억 달러로 평가되었고, 예측 기간인 2025-2032년 CAGR 13.6%로 성장할 전망이며, 2024년 22억 7,000만 달러에서 2032년에는 63억 달러로 성장할 것으로 예측됩니다.
세계의 지카바이러스 치료제 시장은 감염률 상승, 진행중인 의약품 연구개발, 예방과 백신 접종을 둘러싼 의식의 고조 의해 큰 성장을 이루고 있습니다. 주로 모기에 의해 매개되는 지카열은 특히 열대 지역에서 심각한 출생 이상 및 신경학적 문제를 야기하여 수요를 더욱 촉진하고 있습니다. mRNA 기술과 디지털 모니터링 툴 등의 기술의 진보는 백신 개발과 안전성을 가속화시키고 있습니다. 예를 들어, Moderna의 혁신적인 mRNA-1893 백신은 현재 임상시험 중으로, 살아있는 주식을 이용하지 않고 효율적으로 바이러스와 싸우는 것을 목표로 하고 있습니다. 게다가 AI, 기계 학습, 블록체인 기술의 통합은 백신의 생산과 유통의 효율을 높이고 있습니다. 이러한 혁신은 신뢰를 쌓고 효과적인 치료를 촉진하며 일반 시민을 계몽함으로써 지카바이러스 치료제의 수요를 재구축하고 있습니다.
목차
서문
분석 목적
시장 범위
정의
분석 기법
정보 조달
2차 및 1차 데이터의 수법
시장 규모 예측
시장의 상정 및 제약
주요 요약
시장 개요 및 전망
수급 동향의 분석
부문별 기회 분석
시장 역학 및 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인 및 기회
성장 억제요인 및 과제
Porter's Five Forces 분석
주요 시장 인사이트
주요 성공 요인
경쟁도
주요 투자 기회
시장 생태계
시장 매력도 지수(2024년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
세계의 지카바이러스 치료제 시장 규모 및 CAGR : 백신 유형별(2025-2032년)
시장 개요
불활성화 바이러스 백신
생 약독화 백신
DNA 백신
mRNA 백신
세계의 지카바이러스 치료제 시장 규모 및 CAGR : 검사 유형별(2025-2032년)
시장 개요
분자 검사
혈청학적 검사
세계의 지카바이러스 치료제 시장 규모 및 CAGR : 최종 사용자별(2025-2032년)
시장 개요
병원 및 진료소
연구기관
세계의 지카바이러스 치료제 시장 규모 및 CAGR : 유통 채널별(2025-2032년)
시장 개요
병원 약국
소매 약국
온라인 약국
세계의 지카바이러스 치료제 시장 규모 및 CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 구도
상위 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 기업이 채용한 전략
시장의 최근 동향
주요 기업의 시장 점유율(2024년)
주요 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2022-2024년)
주요 기업 프로파일
Moderna Inc.(USA)
Valneva SE(France)
Inovio Pharmaceuticals, Inc.(USA)
Emergent BioSolutions Inc.(USA)
Novavax, Inc.(USA)
Johnson & Johnson(USA)
Pfizer Inc.(USA)
Bharat Biotech International Ltd.(India)
GeoVax Labs, Inc.(USA)
Takeda Pharmaceutical Company Limited(Japan)
GlaxoSmithKline plc(GSK)(UK)
BioCryst Pharmaceuticals, Inc.(USA)
Zydus Cadila(India)
GeneOne Life Science Inc.(South Korea)
Kimer Med(Spain)
BioVaxys Technology Corporation(Canada)
Creative Diagnostics(USA)
Indian Immunologicals Limited(India)
Sanofi Pasteur(France)
결론 및 권고
AJY
영문 목차
영문목차
Global Zika Virus Therapeutics Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 6.3 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).
The global Zika virus therapeutics market is witnessing significant growth due to rising infection rates, ongoing pharmaceutical research and development, and heightened awareness surrounding prevention and vaccination. Primarily transmitted by mosquitoes, Zika causes severe birth defects and neurological issues, particularly in tropical regions, further driving demand. Technological advancements, such as mRNA technology and digital monitoring tools, have accelerated the development and safety of vaccines. For example, Moderna's innovative mRNA-1893 vaccine is currently in clinical trials, aiming to efficiently combat the virus without utilizing live strains. Additionally, the integration of AI, machine learning, and blockchain technology is enhancing vaccine production and distribution efficiency. These innovations are building trust, promoting effective treatments, and educating the public, reshaping demand in the Zika therapeutics landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Zika Virus Therapeutics Market Segments Analysis
Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Zika Virus Therapeutics Market
The rising incidence of Zika virus, especially in tropical and subtropical areas, is driving the growth of the global Zika virus therapeutics market. Factors such as increased global travel, climate change, urbanization, and the expanding mosquito population are intensifying the need for effective prevention and treatment measures. In response to this growing threat, governments and international health organizations are making substantial investments in Zika virus prevention strategies, further boosting the demand for therapeutics. This surge in investment and awareness is critical in addressing the escalating challenges posed by the Zika virus on public health.
Restraints in the Global Zika Virus Therapeutics Market
The global Zika virus therapeutics market faces significant restraints primarily due to the high costs associated with the development process. These expenses arise from the intricate nature of research and development, along with the necessity for multiple clinical trials prior to vaccine introduction. Additionally, varying acceptance criteria set by regulatory bodies such as the ICMRA in India, the FDA in the United States, and the European Union necessitate ongoing research and heavier investments. Furthermore, many vaccines demand cold storage and efficient cold chain logistics, which subsequently elevate operational costs, thereby posing additional challenges in bringing effective therapeutics to market.
Market Trends of the Global Zika Virus Therapeutics Market
The Global Zika Virus Therapeutics market is witnessing a significant trend towards the advancement of vaccine technologies, particularly with the emergence of mRNA and DNA platforms. These innovative technologies enable faster and more efficient vaccine development, allowing companies to respond swiftly to outbreaks. The accelerated approval process by regulatory bodies, coupled with the growing endorsement from medical organizations, fosters greater acceptance and confidence in these vaccines among the public. As global health agencies prioritize Zika virus prevention, the market is poised for robust growth, driven by enhanced research activities, collaborative efforts, and increased investment in novel therapeutic solutions.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2025-2032)
Market Overview
Inactivated Virus Vaccine
Live Attenuated Vaccine
DNA Vaccine
mRNA Vaccine
Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2025-2032)
Market Overview
Molecular Test
Serological Test
Global Zika Virus Therapeutics Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals and Clinics
Research Institutes
Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Zika Virus Therapeutics Market Size & CAGR (2025-2032)
North America (Vaccine Type, Test Type, End User, Distribution Channel)
US
Canada
Europe (Vaccine Type, Test Type, End User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
